SmithKline complement protein research spin-off AdProTech raises $7.9 mil. in venture capital.
Executive Summary
SMITHKLINE BEECHAM COMPLEMENT PROTEIN RESEARCH SPIN-OFF ADPROTECH will begin operations with $7.9 mil. ([pound]5 mil.) in venture capital funding from 3i, Alta Berkeley Associates and Prelude Trust. SB's divestiture plan for its complement protein research program will give AdProTech a portfolio of patents, associated research assets and a group of key researchers in exchange for a 10% stake. SmithKline funded a six-month change-over period that ended in July, during which AdProTech's operations were supported by SB and the new firm continued to work at SmithKline's facilities. SB will not provide continuing financial support.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth